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Background: The optimal management of mitral regurgitation (MR) in patients with severe systolic dysfunction is controversial. Single center 
studies have shown that mitral valve replacement (MVR) confers long durability but high operative mortality. We have adopted a technique for MVR 
with chordal sparing through a 5-cm right antero-lateral thoracotomy without aortic cross-clamp. We hypothesized this technique offers low mortality 
in patients with left ventricular ejection fraction ≤ 35%.
Methods: Between 1/06 and 8/09, 66 patients with LVEF ≤ 35% underwent full chordal sparing minimally-invasive MVR (mini-MVR) under cold 
fibrillatory arrest and without aortic cross-clamp. Using an institutional database, we examined clinical, echocardiographic, and operative outcomes.
Results: 66 patients (74%M, 26%F), mean age 65 ± 10 yrs underwent mini-MVR. Clinical, echocardiographic, and operative data are shown in 
Table 1. Sixteen patients (24%) had LVEF ≤ 20%. Observed vs. expected Society of Thoracic Surgery (STS) 30 day mortality was 4.5 vs. 6.5% for total 
cohort, 5.6 vs. 7.4% for EF ≤ 20%, and 9.1 vs. 17.9% for STS-predicted mortality ≥10%. 
Table 1. Clinical, Echocardiographic, and Operative Data (mean ± SD)
NYHA Class 3.1 ± 0.6
Previous Coronary Artery Bypass 33 (50%)
Etiology of Mitral Regurgitation:
Ischemic:
Non-Ischemic:
44 (67%)
22 (33%)
Type of Replacement Valve
Bioprosthetic:
Mechanical:
63 (96%)
3 (4%)
Prior Myocardial Infarction 24 (36%)
Prior Stroke 21 (32%)
Pre-operative EF, % (n = 66) 25.8 ± 7.3 (median 25, range 8-35)
Pre-operative Left Ventricular End-diastolic Dimension, cm (n = 52) 6.4 ± 1.0
Pre-operative Right Ventricular Systolic Pressure, mmHg (n =39) 51.9 ± 16.1
Fibrillatory Arrest Time, min (n = 59) 86.9 ± 23.9
Cardiopulmonary Bypass Time, min (n = 59) 120.4 ± 32.7
Total Operative Time, min (n = 59) 273.6 ± 54.3
Length of ICU Stay, days (n = 59) 4.4 ± 3.7
Total Transfusions (units/per patient) 2.0 ± 3.0
Post-operative Stroke 1/66 (1.5%)
Post-operative Renal Failure (Creatinine > 2 and 2x pre-operative level) 2/66 (3.0%)
Conclusions: In patients with LVEF ≤ 35%, mini-MVR with chordal sparing and without aortic cross-clamp is safe and associated with favorable 
operative mortality and morbidity compared to STS-predicted rates.
